AI assistant
Moderna, Inc. — Director's Dealing 2022
May 12, 2022
30610_dirs_2022-05-12_f251ceef-73cf-48a8-b3be-7960b90edfd7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-05-11
Reporting Person: Meline David W (Chief Financial Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 2583 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $149.52 | 2032-03-01 | Common Stock (26020) | Direct | |
| Restricted Stock Units | $0 | Common Stock (6415) | Direct | ||
| Restricted Stock Units | $0 | Common Stock (3830) | Direct | ||
| Stock Option (Right to Buy) | $179.52 | 2031-02-09 | Common Stock (25618) | Direct | |
| Stock Option (Right to Buy) | $59.15 | 2030-07-06 | Common Stock (271303) | Direct |
Footnotes
F1: 25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F2: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F3: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F4: 25% of this option vested and became exercisable on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F5: 25% of this option vested and became exercisable on July 6, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.